Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS-650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis C
Article first published online: 16 AUG 2013
© 2013, The American College of Clinical Pharmacology
Clinical Pharmacology in Drug Development
Volume 2, Issue 4, pages 316–327, October 2013
How to Cite
Eley, T., He, B., Huang, S.-P., Li, W., Pasquinelli, C., Rodrigues, A. D., Grasela, D. M. and Bertz, R. J. (2013), Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS-650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis C. Clinical Pharm in Drug Dev, 2: 316–327. doi: 10.1002/cpdd.52
- Issue published online: 8 OCT 2013
- Article first published online: 16 AUG 2013
- Manuscript Accepted: 12 JUL 2013
- Manuscript Received: 13 AUG 2012
Options for accessing this content:
- If you are a society or association member and require assistance with obtaining online access instructions please contact our Journal Customer Services team.
- If your institution does not currently subscribe to this content, please recommend the title to your librarian.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
- New Users: Please register, then proceed to purchase the article.
Login via OpenAthens
Search for your institution's name below to login via Shibboleth.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!